Singleron Biotechnologies is an innovative molecular diagnostic company.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 10, 2021 | Series B | $100M | 2 | — | — | Detail |
Sep 6, 2020 | Series A | $30M | 2 | Lilly Asia Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series B |
Lilly Asia Ventures | — | Series B |